Medicines labeled for the same conditions
Alternatives to ertugliflozin and sitagliptin
29 other medicines are given the same way (oral) and in the same FDA class as ertugliflozin and sitagliptin or labeled mainly for the same use (type 2 diabetes); 9 are in its class, dipeptidyl peptidase 4 inhibitors: alogliptin, alogliptin and pioglitazone, linagliptin and metformin, metformin and saxagliptin and 5 more; the others include 5 sulfonylureas, 5 sodium-glucose cotransporter 2 inhibitors and 3 peroxisome proliferator receptor gamma agonists (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $1.04 per saxagliptin HCl 5 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as ertugliflozin and sitagliptin?
The first 24 of the 29, the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Ertugliflozin and sitagliptindipeptidyl peptidase 4 inhibitor | this medicine | none listed | $17.59 per tablet 15-100 mg tablet | No | No current entry |
| Alogliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | none listed | $4.96 per tablet 12.5 mg tablet | No | No current entry |
| Alogliptin and pioglitazoneperoxisome proliferator receptor gamma agonist · same class | Type 2 diabetes | none listed | $4.73 per tablet 25-15 mg tablet | Yes | No current entry |
| Linagliptin and metformindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | 1 labeler | $8.44 per tablet 2.5 mg-1,000 mg tablet | Yes | No current entry |
| Metformin and saxagliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | 2 labelers | $9.65 per tablet 5-1,000 mg tablet | Yes | No current entry |
| Saxagliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | 3 labelers | $1.04 per tablet 5 mg tablet | No | No current entry |
| Alogliptin and metformindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | none listed | $2.46 per unit 12.5-1000 | Yes | No current entry |
| Empagliflozin and linagliptin and metforminsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | $11.28 per tablet 10-5-1,000 mg tablet | Yes | No current entry |
| Linagliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | none listed | $16.80 per tablet 5 mg tablet | No | No current entry |
| Empagliflozin and linagliptinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | $11.24 per tablet 10 mg-5 mg tablet | No | No current entry |
| Metforminbiguanide | Type 2 diabetes | 83 labelers | $0.0145 per tablet 500 mg tablet | Yes | No current entry |
| Glipizidesulfonylurea | Type 2 diabetes | 31 labelers | $0.0339 per tablet 5 mg tablet | No | No current entry |
| Glimepiridesulfonylurea | Type 2 diabetes | 29 labelers | $0.0507 per tablet 4 mg tablet | No | No current entry |
| Pioglitazoneperoxisome proliferator receptor gamma agonist | Type 2 diabetes | 22 labelers | $0.0675 per tablet 15 mg tablet | Yes | No current entry |
| Glyburidesulfonylurea | Type 2 diabetes | 16 labelers | $0.0643 per tablet 5 mg tablet | No | A presentation being discontinued |
| Dapagliflozin and metforminsodium-glucose cotransporter 2 inhibitor | Type 2 diabetes | 8 labelers | $0.720 per tablet 10-1,000 mg tablet | Yes | No current entry |
| Glyburide and metforminsulfonylurea | Type 2 diabetes | 11 labelers | $0.171 per unit 2.5-500 mg | Yes | No current entry |
| Glipizide and metforminsulfonylurea | Type 2 diabetes | 9 labelers | $0.242 per unit 2.5-250 mg | No | No current entry |
| Repaglinideglinide | Type 2 diabetes | 7 labelers | $0.0987 per tablet 1 mg tablet | No | No current entry |
| Nateglinideglinide | Type 2 diabetes | 9 labelers | $0.179 per tablet 60 mg tablet | No | No current entry |
| Acarbosealpha-glucosidase inhibitor | Type 2 diabetes | 6 labelers | $0.274 per tablet 100 mg tablet | No | No current entry |
| Metformin and pioglitazoneperoxisome proliferator receptor gamma agonist | Type 2 diabetes | 5 labelers | $0.283 per unit 15-500 | Yes | No current entry |
| SemaglutideGLP-1 receptor agonist | Type 2 diabetes | none listed | $33.13 per tablet 1.5 mg tablet | Yes | A presentation being discontinued |
| Canagliflozin and metforminsodium-glucose cotransporter 2 inhibitor | Type 2 diabetes | none listed | $9.58 per tablet 150-1,000 mg tablet | Yes | No current entry |
| Empagliflozin and metforminsodium-glucose cotransporter 2 inhibitor | Type 2 diabetes | none listed | $5.60 per tablet 12.5-1,000 mg tablet | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Ertugliflozin and sitagliptin: the full record
- label, generics, price, shortages, recalls